In Brief: An abnormal cognitive screen marks the first step in a structured evaluation for cognitive impairment. In the 30 days that follow, for a clinically stable patient, a PCP can confirm the concern, stage function, look for modifiable contributors, review medications, address safety, and give the patient and care partner a clear plan. Referral may be part of that plan, but it should not create a period of clinical inactivity. Dementia management should begin in primary care.
When a cognitive screen comes back abnormal, many primary care clinicians feel an understandable hesitation. An abnormal result raises questions the appointment was not booked to answer, and the patient and family may be anxious. The next step can feel as though it belongs somewhere else, in neurology, geriatrics, neuropsychology, or a memory clinic.
Referral has its place, but the first response to cognitive impairment that has been detected does not have to be a handoff. Most people living with dementia receive their ongoing care in primary care settings rather than in specialty clinics, and fewer than half of dementia cases are recognized and documented there. In many cases, dementia management in primary care is exactly where the work should begin.
The screen itself only identifies risk. Turning that risk into action happens in the visits that follow: confirming the concern, looking for modifiable contributors, establishing a functional baseline, bringing a family member into the plan, reviewing medications, assessing safety, and deciding when specialty input is necessary. None of those steps require the patient to wait passively for a specialist appointment.
The Cost of Waiting Between Screening and Specialty Care
In dementia care, time is not neutral. By the time a screen is abnormal, there may already be missed appointments, unpaid bills, medication mistakes, driving concerns, caregiver strain, or a subtle loss of independence that no one has named yet. Access to specialty care is uneven, and 55% of primary care physicians report that their communities do not have enough dementia care specialists. During that waiting interval, the family is still making daily decisions, the patient is still taking the same medications, and safety risks keep evolving.
Some cases do need a specialist. Atypical presentations, rapid progression, early-onset symptoms, prominent movement disorder or hallucinations, diagnostic uncertainty, major behavioral symptoms, or possible eligibility for disease-modifying Alzheimer's therapy may require specialist involvement. But the existence of those referral pathways should not imply that primary care has nothing to do while the patient waits.
Primary care physicians are often the clinicians who know the patient best: the baseline, the family dynamics, the comorbidities, the medications, the living situation, the tolerance for complex care plans. In dementia care, those details are the raw material of the care plan.
Many of the highest-value early steps are familiar primary care work: history-taking, medication review, risk stratification, family engagement, depression screening, lab evaluation, chronic disease optimization, and anticipatory guidance. Dementia adds emotional weight to each of those tasks, but it does not make any of them less familiar to primary care physicians (PCPs).
What the First 30 Days After an Abnormal Screen Can Accomplish
Immediately: Determine Whether the Change Is Urgent
Cognitive change that appeared quickly, or that comes and goes, is a different problem from change that developed over years. If the patient is clinically stable, they can proceed to a scheduled evaluation.
Within 1 to 2 Weeks: The Dedicated Evaluation
1. Confirm the Concern
Review the cognitive screen in context. Ask what the patient has noticed, what the family has noticed, and what has changed in daily life. If the screening result is abnormal, follow with a more detailed cognitive assessment or arrange one within the practice workflow. The workup after an abnormal screen rests on clinical judgment, focused on ruling out modifiable causes and deciding whether further evaluation is needed.
A multidomain cognitive assessment can help characterize whether performance is lower than expected, and in which domains. The clinician must interpret those findings alongside the patient's history, information from someone who knows the patient well, functional change, medication exposure, mood, sleep, sensory limitations, physical and neurologic examination, laboratory testing, and structural imaging.
2. Stage the Problem Functionally
Cognitive scores alone do not distinguish mild cognitive impairment from dementia. The critical question is whether cognitive change is interfering with independent everyday function, and whether that loss is cognitive rather than physical, sensory, or environmental in origin.
One question often tells me more than another point on a cognitive test: what has someone else quietly started doing for this patient? Ask not only whether bills, medications, meals, transportation, and appointments get done, but who does them, how reliably, and at what risk.
3. Look for Reversible or Modifiable Contributors
Common contributors include depression, sleep disorders, medication effects, alcohol use, delirium, sensory impairment, metabolic abnormalities, B12 deficiency, thyroid disease, anemia, renal or hepatic dysfunction, and uncontrolled vascular risk factors.
Not every contributor is the cause, but many are worth treating. Primary care clinics see a markedly higher share of patients whose cognitive symptoms trace to depression, sleep disturbance, or medication effects than specialty memory clinics do, which is part of why this evaluation belongs where the patient already is.
4. Review Medications With Cognition in Mind
Ask whether every medication still has a clear indication, whether it is helping, whether the regimen can be simplified, and whether the patient can still take it safely. Review anticholinergic and sedative burden, orthostasis, hypoglycemia risk, adherence, and drug interactions. Deprescribing is a monitored clinical process, not a one-time deletion from the medication list.
The review should cover over-the-counter diphenhydramine and doxylamine, alcohol and cannabis, and any high-risk combinations. The 2023 AGS Beers Criteria advise avoiding strong anticholinergics in patients with cognitive impairment. Benzodiazepines and similar medications should not be abruptly stopped.
By Day 30: Build the First Care Plan
The first care plan does not need to solve management for the next five years. It should name the problem, identify the care partner, address immediate safety risks, define follow-up, and give the family a point of contact. A written care plan helps patients and caregivers leave with something more useful than fear.
Safety domains to evaluate include:
- Driving and transportation
- Medication administration
- Falls and wandering
- Cooking and fire risk
- Firearms
- Financial exploitation and scams
- Living alone, self-neglect, or abuse
- Emergency and backup care plans
Identifying the care partner means more than writing down a name. Assess willingness, ability, health, burden, backup support, and need for education or respite.
Cognitive impairment does not automatically mean loss of decision-making capacity. Capacity is decision-specific and may fluctuate. Use supported decision-making, keep the patient at the center of planning, identify a health care proxy, and begin advance care planning while the person can participate fully.
When 30 Days Is Too Long
30 days is an operating target, not a reason to wait. Acute or fluctuating cognitive change, altered attention, focal neurologic findings, seizure, systemic illness, rapid functional loss, severe behavioral danger, or an immediate driving, medication, firearm, or home safety risk requires same-day or emergency evaluation.
Screening Without Follow-Through Is Unfinished Care
The primary care clinician owns the plan but does not perform every task alone. Nurses can gather collateral history and close follow-up loops. Pharmacists can address medication burden. Social workers and care managers can address caregiver strain, benefits, transportation, and home safety.
At a system level, every abnormal screen should trigger a closed loop: a responsible clinician, a defined next step, a timeframe, and confirmation that the patient and care partner understand the plan.
The Same Framework Applies as Dementia Progresses
Early dementia management is not a separate playbook for every stage. The same questions repeat, but the answers change:
-
In mild disease, the focus is on preserving independence, planning early, managing vascular and psychiatric comorbidities, reviewing medications, and helping the patient participate fully in decisions.
-
In moderate disease, the focus shifts toward caregiver partnership, supervision, behavioral symptoms, safety, and simplification.
-
In severe disease, the care plan centers on comfort, function, caregiver support, goals of care, and avoiding burdensome interventions that do not match the patient's values.
The primary care physician does not need to predict the entire trajectory at the first visit. The goal is to create a reliable process: measure, discuss, plan, follow up, and revise.
Where New Alzheimer's Disease Treatments Fit
Disease-modifying Alzheimer's therapies have raised the stakes for early detection. Anti-amyloid therapies are not appropriate for every patient. They are indicated for early symptomatic Alzheimer's disease, meaning mild cognitive impairment or mild dementia, with confirmed amyloid pathology, and they require careful confirmation, eligibility review, risk discussion, and monitoring.
These treatments modestly slow decline in carefully selected patients. They do not restore lost cognition or cure Alzheimer's disease. But their availability reinforces the same principle: primary care should not ignore early cognitive impairment simply because a specialist may eventually be involved.
Primary care can complete much of the groundwork that determines whether a referral is appropriate and productive: documenting stage, establishing functional history, gathering medication and anticoagulation information, ordering standard evaluations according to local protocols, and preparing patients and families for a realistic discussion of benefits and risks. Those risks include infusion-related reactions and amyloid-related imaging abnormalities, the latter now prompting additional MRI monitoring early in treatment.
Why PCP Confidence Is a Clinical Intervention
When a PCP hesitates, the patient's care usually pauses with them. Half of primary care physicians report that they do not feel adequately prepared to care for patients with Alzheimer's and other dementias.
Families can sense when a clinician is reluctant to name the problem or unsure what to do next. They can also feel the difference when a clinician says, "We have enough information to start. We will keep evaluating, we will bring in specialists when needed, and we will not leave you alone with this." Confidence does not mean certainty. It means being able to explain what we know, what remains uncertain, what we will do next, and when the patient will hear from us again.
Primary care does not have to provide every part of dementia care to prevent a dangerous gap after screening. It does need a reliable process to recognize urgency, characterize the clinical picture, assess function and safety, address contributors, involve a care partner, and close the loop. The goal is not to label the patient quickly. It is to make the next step safe, clear, and patient-centered.
Written by Dr. Anthony Zizza, Chief Medical Officer, Element Care
Dr. Zizza is a board-certified geriatrician and chief medical officer at Element Care, a PACE (Program of All-Inclusive Care for the Elderly) organization, where he integrates cognitive care within value-based frameworks. He earned his MD at the University of Massachusetts and completed a fellowship in Geriatric Medicine at Harvard. He serves as an advisory board member at Creyos.